A-674563 is a potent, selective and orally available AKT inhibitor with Ki of 11 nM (Akt1).
A-674563 increases the efficacy of paclitaxel in a PC-3 xenograft model.
A-674563 enhances the transcription of several chondrocyte marker genes, including Col2a1, Acan and Col11a2, in mouse primary chondrocytes by inhibiting Sox9 degradation through the ubiquitin-proteasome pathway.
A-674563 also suppresses FLT3-ITD positive AML both in vitro and in vivo.
